BME:ALMPharmaceuticals
Almirall (BME:ALM) EPS Rebound Tests Bullish Growth Narratives Despite Rich 59.8x P/E
Almirall FY 2025: Earnings Momentum Meets Rich Valuation Debate
Almirall (BME:ALM) has capped FY 2025 with fourth quarter revenue of €310.6 million and net income of €7.1 million, while its trailing 12 month EPS stands at €0.22 on net income of €46.2 million. This sets a clear earnings benchmark for investors watching its recent turnaround. The company has seen trailing 12 month revenue move from €990.6 million at the end of 2024 to €1.14 billion by the close of 2025, with trailing EPS...